BNET Industries
Today’s Top Pharma News and Analysis
-
Lilly's Zyprexa shot faces FDA delay
Fierce Pharma -
10 hours 12 minutes ago
Eli Lilly announced Wednesday that the FDA has delayed approval of a long acting version of its schizophrenia drug olanzapine pending a proposal for a Risk Evaluation and Mitigation Strategy (REMS). The company says it will submit the proposal in the "near future," but did not offer a time period. "We cannot...
-
GSK taps Wynonna to pitch Alli
Fierce Pharma -
15 hours 51 minutes ago
Look for a new marketing push behind GlaxoSmithKline's weight-loss drug Alli. The company signed Wynonna Judd to campaign for the over-the-counter pill on TV and the web; GSK already has a Judd-centered Alli website online, BNet Pharma reports. Presumably the media buy isn't far behind. Meanwhile, Glaxo is hoping to...
-
Synosia raises CHF32 million in series B financing
Pharmaceutical Business Review -
22 hours 44 minutes ago
Synosia Therapeutics, a developer of clinically differentiated products for unmet medical needs in psychiatry and neurology, has completed a CHF32 million series B private financing...
-
Boston Scientific buys new stent company
Fierce Pharma -
1 day ago
Boston Scientific has acquired Labcoat Limited, a company that focuses on drug-eluting stent technology, under undisclosed terms. Boston Scientific said in a press release that Labcoat has developed a new technology for coronary stents.Wire-mesh stents can help keep arteries open after they are unclogged. Drug-eluting stents are coated in medications...
-
AZ seeks nasal flu vaccine approval
Fierce Pharma -
1 day ago
AstraZeneca's MedImmune submitted a new drug application in Europe to market its nasal spray flu vaccine, according to a company press release. The FDA approved the same nasal spray in 2003, which AstraZeneca markets as FluMist in the United States. Currently, clinicians give the flu vaccine by injection only in Europe. If approved,...
-
Endo Pharmaceuticals to acquire Indevus Pharmaceuticals for $370 million
Pharmaceutical Business Review -
2 days ago
Endo Pharmaceuticals and Indevus Pharmaceuticals have entered into a merger agreement under which Endo will commence a tender offer to acquire 100% of the outstanding shares of Indevus for approximately $370 million, or $4.50 per Indevus share, in cash...
-
Pfizer?s Big Acquisition ? Is a Tiny Rights Deal With Cytos
BNET Insight -
2 days ago
The world continues to fuliminate over the notion that Pfizer is poised to make a big deal. Could it be Amgen? Could it be Bristol-Myers Squibb? The speculation reached a new height of ridiculousness with this column in Today’s Financial News, “Pfizer shouts its message to the world.” The writer...
-
Merck asks FDA to expand Gardasil use
Fierce Pharma -
2 days ago
Anyone who's been following the vaccine trade knows that Merck is working hard to expand the use of its human papillomavirus shot. Now approved for marketing to girls and young women, Gardasil has been tested on boys, young men and on women as old as 45, with the aim of...
-
Cigna to axe 1,100 jobs
Pharmaceutical Business Review -
2 days ago
Cigna, an investor-owned health service organization, has announced that it will reduce its global workforce by approximately 1,100 positions, around 4% of the company's employees, and also consolidate certain real estate locations...
-
PPD acquires Merck's vaccine testing lab
Pharmaceutical Business Review -
2 days ago
PPD, a contract research organization, has entered into a strategic collaboration with Merck & Co, involving vaccine testing and assay development. Under the agreements, PPD purchased Merck's 130,000 square-foot vaccine testing laboratory and related equipment in Wayne, Pennsylvania, and hired the nearly 80 Merck professionals who operate this facility. Financial...
- Pharma Roundup: Merck CEO Admits Failure, Lilly’s New Zyprexa Delay, and More
- Inspire Withdraws From Allergan’s Restasis Effort
- Boehringer Reps’ Get Legal Victory on Back Pay; Amgen, Serono Reps Could Be Affected
- Pharma Roundup: Pfizer’s Lipitor Patent, Wyeth and Crucell, and More
- The Pfizer-Shire Deal Worst-Case Scenario
- GSK Signs Wynonna Judd to Endorse Alli, Its Flagging Weight Loss Drug
- Pharma Roundup: Daiichi’s Ranbaxy Write-Down, Merck’s UPS Deal, and More
- Pharmalot’s Ed Silverman: The Exit Interview
- Pfizer’s Big Acquisition … Is a Tiny Rights Deal With Cytos
- List of 56 Drugs That Should Not Be Mixed With Viagra Contains Some Surprises
- More Pharma Insights
Top Rated
- GSK Employees Really Love Their Boss's Book -- It's "Better Than Harvard"!+137 votes
- Roche-Genentech: Desperation Is On the Rise+123 votes
- Wyeth, Elan and Bapineuzumab -- How to Lie With (Drug) Statistics+121 votes
- Pfizer Courting More Controversy with Viagra 'Advergaming'+98 votes
- Genentech Finds No Friends in Lucentis Pricing Flap+83 votes
- Top 10 Weirdest Pharma Stories of the Month+45 votes
- A Worst-Case Scenario in the Roche-Genentech Bid+43 votes
- Pharma's Future Leaders -- Or Its Pallbearers+40 votes
Recommended Sources
Subscribe
Archives
AboutPharma Industry
BNET Pharma provides daily industry news coverage and insights for managers and executives about the major manufacturers of pharmaceuticals and medicine. In addition to detailed company profiles, we bring you critical analysis on new alliances and partnerships, new patents and products, mergers and acquisitions, cost management, investments and deal flow, and a host of other important business issues.
